SARS-CoV-2 dependence on host pathways.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Can plitidepsin be used as an antiviral against RSV?mSphere · 2025
   Article
2. A Bifunctional SARS-CoV-2 Entry Inhibitor Targeting the Host Protease TMPRSS2 and Viral Spike Protein HR1 Region.International journal of molecular sciences · 2025
   Article
3. Biological characteristics of SARS-CoV-2 resistant populations by integrated gut microbiota sequencing, metabolomics, and proteomics: a cohort comparison study.Frontiers in medicine · 2025
   Article
4. Role of marine natural products in the development of antiviral agents against SARS-CoV-2: potential and prospects.Marine life science & technology · 2024
   Review
5. Differential abundance of lipids and metabolites related to SARS-CoV-2 infection and susceptibility.Scientific reports · 2023
   Article
6. Targeting RNA G-quadruplex with repurposed drugs blocks SARS-CoV-2 entry.PLoS pathogens · 2023
   Article
7. Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.European journal of medicinal chemistry · 2022
   Review
8. Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (MComputers in biology and medicine · 2022
   Article
9. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.Nature · 2022
   Article
10. Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2.Pharmacology & therapeutics · 2022
    Review
11. Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice.Communications biology · 2022
    Article
12. Promising Assays for Examining a Putative Role of Ribosomal Heterogeneity in COVID-19 Susceptibility and Severity.Life (Basel, Switzerland) · 2022
    Review
13. Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2.ImmunoTargets and therapy · 2022
    Review
14. Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.Frontiers in pharmacology · 2022
    Review
15. An update of anti-viral treatment of COVID-19Turkish journal of medical sciences · 2021
    Review
16. Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19.Journal of personalized medicine · 2021
    Review
17. Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19.The Journal of clinical investigation · 2021
    Article
18. Integrating evolutionary aspects into dual-use discussion: the cases of influenza virus and enterohemorrhagicEvolution, medicine, and public health · 2021
    Review
19. Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.Frontiers in immunology · 2021
    Review

Corrections and comments

• Comment on
  Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.2021

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as